A high-throughput mass spectrometry assay to measure the catalytic activity of phosphatidylserine decarboxylase (PISD) is described. PISD converts phosphatidylserine to phosphatidylethanolamine during lipid synthesis. Traditional methods of measuring PISD activity are low throughput and unsuitable for the high-throughput screening of large compound libraries. The highthroughput mass spectrometry assay directly measures phosphatidylserine and phosphatidylethanolamine using the RapidFire™ platform at a rate of 1 sample every 7.5 s. The assay is robust, with an average Z′ value of 0.79 from a screen of 9920 compounds. Of 60 compounds selected for confirmation, 54 are active in dose-response studies. The application of high-throughput mass spectrometry permitted a high-quality screen to be performed for an otherwise intractable target. (Journal of Biomolecular
INTRODUCTION
M ASS SPECTROMETRY is an emerging format for highthroughput screening (HTS) of compound libraries to identify leads for drug-discovery programs. [1] [2] [3] [4] [5] [6] Mass spectrometry permits the direct detection of unmodified analytes of diverse structures and so provides a format that is potentially free of pragmatic or economic limitations due to labeling or capture technologies. However, the presence of high concentrations of nonvolatile ionic compounds, such as commonly used salts or buffers, results in ion suppression and degradation of instrument performance. Coupled liquid chromatography-mass spectrometry (LC-MS) systems overcome problems associated with buffer composition. Cycle times with LC-MS systems are typically 1 to 4 min, however, which precludes screening of large compound libraries.
Various approaches have been taken to increase the throughput of mass spectrometry for HTS. One approach is to decouple the sample purification and analysis steps in which a parallel sample purification protocol (usually 96-well solid-phase extraction plates) is followed by subsequent serial mass spectrometry analysis. 7 This technique is expensive and labor intensive and not compatible with most existing laboratory automation. Another approach involves interfacing multiple liquid chromatography systems to a single mass spectrometer. 8 This approach staggers sample injections and collects only relevant elution windows from each chromatographic system. This style of system is ultimately limited by peak width (typically in the 20-30 s range), which dictates throughput if baseline resolved data are desired. Peaks can be sharpened by increasing flow rates and/or lowering column bed volumes. This can, however, result in diminished loading capacities as well as lower sensitivity. Some manufacturers of mass spectrometers have attempted to increase throughput by designing mass spectrometry sources that enable simultaneous analysis of multiple liquid chromatography columns. 9,10 A disadvantage to this approach is that the sensitivity is effectively divided by the number of liquid chromatography systems used. Others have used matrix assisted laser desorption/ionization (MALDI)-based systems. 6 Unfortunately, MALDI instrumentation is not as quantitative or reproducible as the electrospray counterpart.
RapidFire™ is an automated microfluidic sample collection and purification system that interfaces directly to standard electrospray mass spectrometry instrumentation. The system uses high-speed robotics to directly aspirate fluidic samples from standard 96-well and 384-well plates; rapidly removes nonvolatile assay components such as salts, buffers, and detergents in an online fractionation step; and delivers purified analytes to the mass spectrometer with chromatographic peak widths of approximately 2 to 3 s. A full review of the RapidFire™ system is presented elsewhere. 4 Here we describe the development of a RapidFire™ highthroughput mass spectrometry (HTMS) assay for phosphatidylserine decarboxylase (PISD). PISD (EC 4.1.1.65) is an inner mitochondrial membrane enzyme involved in phospholipid synthesis that catalyzes the conversion of phosphatidylserine (PS) to phosphatidylethanolamine (PE) with the release of CO 2 . 11,12 PE is a major component of lipid membranes and the 2nd most abundant phospholipid, constituting about 20% of the total cellular lipid, with higher amounts found in mitochondria. 12 The decarboxylation of PS by PISD is the major source of PE in some mammalian cell types, 12, 13 and embryonic death and mitochondrial defects are observed in PISD-null mice. 14 Smallinterfering RNA targeting PISD in HCT116 cells decreased PE production, inhibited proliferation, and induced apoptosis (W. Pickett and others, unpublished data). Taken together, these observations suggest that PISD may contribute to cancer cell growth and survival (W. Pickett and others, unpublished data).
Established assays for PISD activity rely on the conversion of 3 H-labeled PS to PE and subsequent analysis with thin-layer chromatography, 15 which is not amenable to HTS, or detection of 14 CO 2 release from 14 C-labeled phosphatidylserine, 15 a substrate that is not readily available in the quantities required for HTS. Because PISD is intractable to currently available HTS approaches, an HTMS assay was developed using a custombuilt microfluidic sample preparation robot and an electrospray mass spectrometer.
METHODS

Reagents
PISD corresponds to the full-length human PISD proenzyme (accession no. CAG30426) 16 that is self-processed to an active heterodimer. PISD was expressed as a C-terminal FLAG tag (MDYKDDDDK) fusion protein using a pcDNA3.1 plasmid harboring a PCR product encoding residues 1 to 409 of PISD. The PCR insert was amplified from a human placenta library, and the coding sequence was confirmed with DNA sequencing.
Cell pellets from PISD-transfected HEK 293F cells were dounce homogenized in buffer A (100 mM potassium phosphate, pH 7.5, 250 mM sucrose, 1 mM EDTA, 1 mM 2-mercaptoethanol). The lysate was centrifuged (500g) for 10 min and the pellet dounce homogenized in buffer A. The resuspended pellet was centrifuged (500g) for 10 min. The 2 supernatants were pooled and centrifuged at 15,000g for 10 min. The pellet was suspended in 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, 10% glycerol, and stored at -20 °C. The presence of PISD was confirmed by Western blot using an in-house-generated antibody. A predominant PISD band was not observed using Coomassie-stained sodium dodecyl sulfate polyacrylamide gel electrophoresis, indicating that PISD levels are likely 1% or less. All PISD concentrations are reported as the total protein concentration of the PISD-containing fraction.
Porcine brain L-α-PS and L-α-PE were obtained from Avanti Polar Lipids Inc. (Alabaster, AL; catalog no. 840032 and 841118C, respectively).
Mass spectrometry
The substrate PS and product PE were analyzed with a Sciex API-4000 electrospray mass spectrometer in positive-ion mode using multiple reaction monitoring. For both analytes, the M + H ions were isolated in Q1, and daughter ions were selected in Q3.
PISD HTS assay
Primary screening and dose-response data were collected at Bayer Pharmaceuticals Corporation (West Haven, CT) using a subset of the Bayer compound library. Liquid handling was performed with a CyBi-Well 96 system and a Matrix Technologies Corporation Wellmate. Assays were run at room temperature in 100 mM potassium phosphate, pH 6.8, and 10 mM EDTA. Compound (1 µl) stored in 70% DMSO was transferred into assay buffer (30 µl) in 96-well polypropylene plates (Nunc 249944). The PISD-containing fraction was added to a final concentration of 15 µg/ml (total protein), and the reaction was initiated by adding 50 µl 40 µM PS in 4% ethanol (final PS concentration = 20 µM). The final reaction volume was 101 µl. The reaction was terminated after 60 min with 20 µl 417 mM HCl. Plates were sealed, frozen at -80 °C, and shipped on dry ice to BioTrove, Inc. (Woburn, MA) for HTMS analysis. Thawed samples were diluted 100-fold with 100 mM potassium phosphate buffer, pH 6.8, 10 mM EDTA, 0.05% Triton X-100. Sample (5 µl) was delivered directly from 96-well plates to a proprietary cleanup cartridge (BioTrove column B) to remove nonvolatile buffer and membrane components with H 2 O in a 2.5-s wash cycle. The substrate and product were coeluted to the mass spectrometer in 3.5 s using 80% isopropanol. The entire injection cycle was approximately 7.5 s per well. The chromatography system produced baseline-resolved peaks with widths of approximately 3 s.
No potent PISD inhibitors have been reported in the literature. Therefore, negative control wells contained enzyme heated at 100 °C for 15 min.
In primary screening, compounds were present at 10 µM. In IC 50 determinations, compounds were dosed in duplicate from 1 nM to 30 µM in half-log dilution steps.
Data analysis
Enzyme inhibition is expressed as normalized percentage inhibition, given by
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where x is the percentage conversion given by PE/(PE + PS) × 100 (where PE and PS are the substrate and product mass spectrum peak areas, respectively), and c -+ and c --are the means of the positive (no inhibitor) and negative (boiled enzyme) controls, respectively.
IC 50 values are determined with nonlinear least squares fitting of the change in normalized percentage inhibition with inhibitor assuming that the free ligand concentration approximates the total ligand concentration:
where y is the normalized percentage inhibition at inhibitor concentration L, y f is the normalized percentage inhibition in the absence of inhibitor, y b is the normalized percentage inhibition in the presence of saturating amount of inhibitor, and h is the Hill slope. Z′ is calculated as described elsewhere. 17
K M determination
Assays were run at room temperature in 100 mM potassium phosphate, pH 6.8, 10 mM EDTA, and 0.05% Triton X-100 in 96-well polypropylene plates. Samples contained 12.5, 25, 50, or 100 mM PS. The reactions were initiated by the addition of 25 µg/ml (total protein) PISD to the reaction mixture and were quenched by the addition of an equal volume of 1 M HCl at 0, 15, or 30 min. The 0-min time points were obtained by adding the 1 M HCl prior to initiating the reaction with enzyme. Each time point was run in triplicate. The K M was obtained from a fit to the Michaelis-Menten equation of the rates of product formation at different substrate concentrations using Prism 3.0.3 (GraphPad Software, Inc., San Diego, CA).
RESULTS
Mass spectrometry detection of PS and PE
Singly charged parent ions are observed in positive-ion mode Q1 scans of PS and PE. The substrate and product have a common major daughter ion (m/z = 605.0) that was used to quantify PS and PE in multiple-reaction monitoring mode. The use of daughter ions provides a means to selectively detect PS and PE, in that other parental ions with the same m/z as the PS and PE parent ions are highly unlikely to generate the same daughter ions as PS and PE. In addition, because the mass spectrum intensity is essentially identical for both PS and PE (Fig. 1) , the ratios of PS and PE detected by mass spectrometry provides a direct measure of the percentage conversion of substrate during the PISD-catalyzed reaction.
Limit of quantitation and linear range
The PS HTMS signal is linear from 78 nM to 2.5 µM (Fig. 1) . Z′ is 0.94 at 156 nM, indicating that the HTMS signal can clearly be discerned from background buffer signal at the tested concentrations. Therefore, the limit of quantification is at least 156 nM, which corresponds to 0.3 pmol of PS (2.0 µl injection volume). Results for PE are essentially identical (Fig. 1) . The upper limit of either the PS or PE concentration in the screening samples is 200 nM, and so the HTMS response is linear over the expected concentration range of both substrate and product.
The HTMS intensity of the buffer-only wells exhibits a very slight positive slope as the plate is read (Fig. 1) . This suggests carryover from the analyte samples to the buffer-only samples, which is estimated from the relative slopes of the 2 lines to be approximately 1%. This level of carryover is acceptable for an HTS application to identify test compounds that exhibit >50% inhibition.
K M determination
Enzymatic time courses during which PS concentration is varied were performed to determine the substrate K M . The reaction is linear to at least 30 min as the PS concentration is varied from 12.5 to 100 µM ( Fig. 2A) . The velocity was plotted versus the substrate concentration to determine a K M for PS of 90 ± 8 µM (Fig. 2B) .
Time and enzyme dependence
Product formation is linear with time to at least 60 min as the PISD concentration is varied from 12.5 to 100 µg/ml (Fig. 3A) . The reaction velocity is linear with PISD concentration between 12.5 and 100 µg/ml (Fig. 3B) . 
Effect of DMSO
To determine the effect of DMSO on the assay, a single time point (60 min) experiment was performed as the concentration of DMSO was varied from 0% to 5%. DMSO concentration had no discernable effect on product formation (data not shown).
Stability of acid-quenched samples
The PISD reaction is quenched with 69 mM HCl (final concentration). Data from acid-quenched samples that were either analyzed immediately or after 8 h at room temperature were essentially identical (data not shown), indicating that the samples are stable upon acid quenching.
Frozen-plate stability
Reaction plates are shipped frozen for HTMS analysis. Data from samples that were either analyzed immediately or frozen and stored for 72 h at -80 °C were essentially identical (data not shown), indicating that the samples are stable upon freeze thawing.
Product signal background in enzyme preparation
Significant amounts of endogenous PE, but not PS, are present in the PISD preparation (data not shown). This may cause problems in reactions containing high-enzyme and low-substrate concentrations. Given the relatively high K M of 90 µM (Fig. 2B) , it is ; Fig. 4 ).
Assay quality
An undirected file of 9920 compounds was screened using HTMS. The file contains compounds that fit the Rule of 5 criteria, 18 with a mean molecular weight of 300 ± 78 Da and a calculated cLogP of 2.4 ± 1.9. The number of hydrogen bond donors and acceptors is 1.3 ± 1.2 and 4.0 ± 1.6, respectively. When compared to the Rule of 5, 18 40 compounds show 2 violations and are not expected to be orally available. An additional 750 compounds exhibit 1 violation of the Rule of 5.
Because there are no reported potent inhibitors of PISD, the wells used for inactive controls contained boiled enzyme. Representative data from a screening plate showing positive and negative control wells, multiple wells containing inactive compounds, and 1 well containing a hit are shown in Figure 5 . The sample cycle time was approximately 7.5 s (Fig. 5) , such that a 96-well plate is screened in 12 min.
The HTMS assay has an average Z′ value of 0.79 for control wells and a range of 0.60 to 0.91 for individual plates containing file compounds (Fig. 6) . The high value of Z′ indicates that the HTMS assay for PISD is robust.
Confirmation rate of primary screen
Of the 9920 compounds tested at a concentration of 10 µM, 240 compounds exhibited >50% inhibition of the PISD reaction. The 240 hits were filtered to remove structurally undesirable compounds. The remaining 135 compounds were retested in duplicate at 10 µM. The active compounds from the retesting were then tested in dose response. Of the 60 compounds selected for confirmation in dose-response studies, 54 compounds were 
DISCUSSION
Most traditional HTS formats rely on either a label and/or capture technology to quantify substrate turnover and product formation. Established HTS formats such as scintillation proximity assay and fluorescence resonance energy transfer provide robust approaches to many target classes. There will always be, however, enzymes that are intractable to conventional HTS formats due to the lack of a suitable labeling or capture technology because of synthetic limitations or economic constraints. Mass spectrometry provides a general, label-free approach to quantify enzyme reactions that resist traditional HTS approaches. The RapidFire™ platform used here allows for the rapid sample cleanup that has been the traditional bottleneck to HTMS.
PISD is a potential cancer target that offers a novel mechanism to modulate cell growth via the inhibition of phospholipid production required for cell viability (W. Pickett and others, unpublished data). Established PISD assays are either low throughput (thin-layer chromatography) or employ 14 C-labeled phosphatidylserine, which is not readily available in the quantities required for HTS. The lack of a suitable capture technology or labeled substrate makes PISD intractable to conventional HTS approaches. Therefore, an HTMS assay was developed to screen the enzyme.
The HTMS method for PISD allows for assays to be performed with standard liquid-handling robots and subsequently analyzed with mass spectrometry at a sample throughput of 7.5 s. This allows for moderately rapid screening of compound libraries, although not with the throughput of traditional HTS formats. A primary screen of 9920 drug-like compounds had an average Z′ value of 0.79, and 54 of 60 hits selected for confirmation were active in dose-response studies (IC 50 <15 µM). The assay is therefore robust and reliably identifies PISD inhibitors.
The use of nonlabeled substrates potentially streamlines assay development by eliminating the need for production and validation of surrogate substrates. In the present case, HTMS assay development was rapid, with confirmation of enzyme activity and the initial identification of assay conditions complete within 1 week. Moreover, a membrane preparation containing PISD was used, which illustrates the effectiveness of the cleanup step and the insensitivity of the RapidFire™ platform to native enzyme preparations. This ability to deal with complex protein mixtures can increase the overall efficiency of assay development by reducing the time required to identify purified protein production conditions. A further aspect of triple quadrapole mass spectrometry is the ability to detect daughter ions, which serves to separate the analyte ions from potentially coeluting impurities that have the same m/z as the primary ions but yield different daughter ions. This effectively eliminates compound interference, which is a potential effect in many optical formats that can contribute to false-positive rates and unnecessary effort in confirmation studies.
In conclusion, a high-throughput, label-free mass spectrometry assay for screening PISD has been developed and used to identify druglike inhibitors of the enzyme. The application of HTMS, therefore, permitted a high-quality screen to be performed for an otherwise intractable target. 
